. 2015 Mar 19;10(3):e0119920. doi: 10.1371/journal.pone.0119920

Table 1. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between MC1R variants and histopathological tumor characteristics among first incident cases of invasive melanoma in the GEM Study.

		Consensus		Only r ¹		One R ²		>1 R ²		Only r ¹ vs. consensus		One R ² vs. consensus		>1 R ² vs. consensus
Tumor characteristic		n	%^*	n	%^*	n	%^*	n	%^*	OR ³	95% CI	OR ³	95% CI	OR ³	95% CI
Breslow thickness (mm)
	0.01–1.00	251	18	464	33	562	40	136	10	1.00		1.00		1.00
	1.01–2.00	60	14	141	33	181	43	42	10	1.21	0.85–1.72	1.34	0.95–1.90	1.38	0.83–2.28
	>2.00	49	17	103	33	107	37	32	11	1.12	0.75–1.65	0.94	0.63–1.39	1.02	0.58–1.79
	p = 0.45
Mitoses
	Absent	173	17	315	32	408	41	96	10	1.00		1.00		1.00
	Present	120	16	260	35	293	39	81	11	1.06	0.79–1.43	1.01	0.76–1.36	1.16	0.76–1.78
	p = 0.56
Ulceration
	Absent	267	17	526	33	636	40	158	10	1.00		1.00		1.00
	Present	26	17	47	31	61	40	18	12	0.81	0.48–1.37	0.99	0.59–1.64	1.38	0.67–2.85
	p = 0.85
Tumor infiltrating lymphocytes ^†
	Absent	59	15	126	33	156	41	43	11	1.00		1.00		1.00
	Non-brisk	197	18	367	33	439	39	112	10	0.89	0.61–1.30	0.93	0.64–1.34	1.09	0.63–1.87
	Brisk	34	15	79	34	100	43	21	9	1.07	0.63–1.82	1.09	0.65–1.84	0.93	0.43–2.02
	p = 0.81
Anatomic location
	Trunk or pelvis	158	17	323	34	402	42	73	8	1.00		1.00		1.00
	Head or neck	59	18	123	36	131	39	25	7	1.11	0.75–1.63	0.85	0.58–1.25	0.89	0.48–1.65
	Arms	55	14	137	34	157	39	56	14	1.30	0.88–1.92	1.13	0.77–1.66	2.39	1.40–4.09
	Legs	93	20	138	30	174	38	56	12	0.85	0.60–1.22	0.80	0.56–1.13	1.42	0.84–2.41
	p = 0.002
Clark level
	II	120	17	234	33	294	41	73	10	1.00		1.00		1.00
	III	94	20	154	32	182	38	48	10	0.79	0.56–1.12	0.74	0.53–1.05	0.72	0.43–1.21
	IV & V	79	15	185	34	222	41	56	10	1.28	0.88–1.86	1.36	0.94–1.96	1.36	0.80–2.30
	p = 0.59
Coexisting nevus
	None identified	231	18	442	33	524	40	125	10	1.00		1.00		1.00
	Common acquired	28	12	77	32	102	42	37	15	1.33	0.83–2.14	1.38	0.86–2.19	1.61	0.87–2.97
	Dysplastic	35	17	67	32	89	43	17	8	0.87	0.54–1.38	0.98	0.62–1.54	0.96	0.48–1.93
	Congenital	8	24	11	33	11	33	3	9	0.81	0.30–2.20	0.83	0.30–2.26	0.65	0.14–2.99
	p = 0.16
Histological type
	Superficial spreading	267	18	472	32	577	40	146	10	1.00		1.00		1.00
	Nodular	21	12	67	37	74	40	21	12	1.61	0.98–2.74	1.45	0.85–2.45	1.58	0.77–3.26
	Lentigo maligna	34	17	66	33	80	40	18	9	1.16	0.72–1.88	1.11	0.69–1.78	0.91	0.44–1.89
	Not otherwise specified	40	15	98	36	112	42	19	7	1.41	0.91–2.19	1.25	0.81–1.94	0.89	0.45–1.78
	p = 0.28
Pigmentation
	Present	280	17	545	33	665	40	161	10	1.00		1.00		1.00
	Absent	22	14	53	33	67	41	21	13	1.23	0.71–2.15	1.17	0.68–2.02	1.37	0.66–2.86
	p = 0.54
Regression
	Absent	201	16	410	33	488	40	130	11	1.00		1.00		1.00
	Present	101	17	190	33	241	41	52	9	1.10	0.79–1.54	1.19	0.86–1.65	0.95	0.58–1.56
	p = 0.73
Satellite
	Absent	199	18	374	33	437	39	113	10	1.00		1.00		1.00
	Present	1	8	6	50	3	25	2	17	2.30	0.26–20.15	0.77	0.07–8.80	1.36	0.07–26.83
	p = 0.57
Solar elastosis
	Absent	105	17	206	33	263	42	60	10	1.00		1.00		1.00
	Present	194	17	378	33	453	40	119	10	1.08	0.76–1.52	1.02	0.73–1.43	1.30	0.79–2.14
	p = 0.79
Vertical growth phase
	Absent	106	17	207	33	249	40	60	10	1.00		1.00		1.00
	Present	185	17	364	33	450	40	117	11	1.03	0.75–1.41	1.07	0.79–1.46	1.15	0.73–1.83
	p = 0.77

* Row percentages are presented

^† Potential prognostic factor based on Thomas et al., J Clin Oncology, 2013. Vol. 33, Num. 33: 4252–59

¹ r indicates carriage of V60L, V92M, I115T, R163Q, or rare nonsynonymous variants in the absence of a R variant.

² R indicates carriage of D84E, R142H, R151C, R160W, D294H, nonsense or insertion/deletion variants.

³ ORs are adjusted for center, sex, age at melanoma diagnosis, phenotypic index, and total body mole density